Several Lots of Human Growth Hormone Have Been Recalled
An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.
Innoveix Pharmaceuticals, a compounding pharmacy in Addison, Tex., is voluntarily recalling several lots of compounded drug products. The products are being recalled due to a lack of assurance of sterility. The issues where discovered during a routine inspection by the FDA.
The affected products are injectable sermorelin/ipamorelin 3mg and injectable AOD-9604 3mg. Sermorelin and ipamorelin are human growth hormone secretagogues (GHSs), which are compounds that increase growth hormone release. AOD is a synthetic peptide thought to have potential for weight loss.
To date, Innoveix Pharmaceuticals has not received any reports of adverse events related to this recall.
Sermorelin / Ipamorelin 3mg
- Lot# SIP210; Exp: 12/15/2021
- Lot# SIP215; Exp: 01/14/2022
- Lot# SIP220; Exp: 01/23/2022
AOD-9604 3mg
- Lot# AOD205; Exp: 11/09/2021
- Lot# AOD210; Exp: 11/18/2021
- Lot# AOD 215; Exp: 12/15/2021
- Lot# AOD202; Exp: 11/09/2021
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
